Navigation Links
Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
Date:10/6/2007

- Results of animal studies distinguish liver effects of apoB inhibition

from MTP inhibition and support liver safety of ISIS 301012 - Favorable changes in liver fat metabolism associated with apoB inhibition

but not MTP inhibition - Results presented in an oral session today at DALM Symposium in New York

City - Isis will host a conference call on Monday, October 8, at 8:00 a.m. E.T.

at http://www.isispharm.com

CARLSBAD, Calif., Oct. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced new results of preclinical studies reaffirming the safety profile of ISIS 301012 and enhancing the understanding of its activity in the liver presented by Richard Lee, Ph.D. of Isis in a 3:45 p.m. oral session today at the Drugs Affecting Lipid Metabolism (DALM) XVI International Symposium in New York City. Isis will host a conference call Monday morning at 8:00 a.m. E.T. to discuss these results along with results of Phase 2 studies of ISIS 301012 presented at DALM.

The preclinical data presented provide a mechanistic explanation for Isis' previous observations that, in mice and monkeys, treatment with antisense inhibitors of apolipoprotein B-100 (apoB) is associated with reduced liver fat content. This observation is in contrast to the effects of either small molecule or antisense inhibitors of microsomal triglyceride transfer protein (MTP), another component of the cholesterol export pathway, which cause severe liver fat accumulation in the same animal models.

In the study reported today at DALM, Isis demonstrated that apoB inhibit
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes 2Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes 3Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes 4Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 3Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 4One of the Largest Wendys 28R 29 Franchisees Tar Heel Capital Reduces Fraud and Slashes Costs with DigitalPersona 8916 1One of the Largest Wendys 28R 29 Franchisees Tar Heel Capital Reduces Fraud and Slashes Costs with DigitalPersona 8916 2Fallopian tubes offer new stem cell source 12704 1Study highlights massive imbalances in global fertilizer use 8914 1Study highlights massive imbalances in global fertilizer use 8914 2Study highlights massive imbalances in global fertilizer use 8914 3Study highlights massive imbalances in global fertilizer use 8914 4Study highlights massive imbalances in global fertilizer use 8914 5
Other Medicine News:Health News:Newborns exposed to maternal smoking more irritable, difficult to soothe 2Health News:Serotek First to Offer 64-Bit Support 2Health News:MRSA and C. difficile Infections Reduced by 50% in Hospital Study 2Health News:MRSA and C. difficile Infections Reduced by 50% in Hospital Study 3Health News:TFAH Statement: FDA Food Protection Plan is Insufficient 2Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 2Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 3Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 4Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 5Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 6Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 7